Decoding Resistance to Targeted Therapy via New Cancer Models

Why It Matters

By providing readily accessible, genetically matched resistant and sensitive models, researchers can rapidly pinpoint vulnerabilities and test combination regimens, accelerating the fight against therapy‑resistant lung cancer. This open‑source resource lowers the barrier to discovery, potentially shortening the timeline for new, durable treatments.

Key Takeaways

• ATCC and Broad engineered isogenic NSCLC models resistant to osimertinib.
• Six resistance mechanisms include PIK3CA, KRAS, BRAF, EGFR C797S, RET, NTRK1 fusions.
• Models integrated into DepMap and new Response and Resistance Map (ResMap).
• Open access distribution accelerates discovery of combination therapies.
• Platform scalable to other cancer types and resistance pathways.

Pulse Analysis

The emergence of resistance to targeted therapies remains a critical hurdle in oncology, especially for EGFR‑mutant non‑small cell lung cancer treated with osimertinib. Traditional patient‑derived resistant models are scarce and time‑consuming to develop, leaving a gap in mechanistic understanding. ATCC and the Broad Institute’s engineered isogenic cell lines fill this void by precisely inserting clinically relevant mutations and fusions, allowing scientists to isolate the impact of each resistance driver while keeping the genetic background constant. This methodological clarity accelerates hypothesis testing and reduces experimental noise.

Beyond the technical advance, the integration of these models into the Cancer Dependency Map (DepMap) and the emerging Response and Resistance Map (ResMap) creates a shared data ecosystem. Researchers worldwide can query genetic vulnerabilities, screen drug libraries, and explore synthetic lethal interactions directly linked to specific resistance mechanisms. Open distribution through ATCC ensures that academic labs, biotech firms, and pharmaceutical companies can access high‑quality, authenticated lines without the lengthy procurement cycles typical of patient‑derived samples. The collaborative framework also encourages cross‑institutional validation, fostering reproducibility and accelerating translational pipelines.

The broader implication is a scalable blueprint for tackling resistance across oncology. By extending the same CRISPR‑based engineering approach to other tumor types and therapeutic classes, the scientific community can build a comprehensive library of resistant models, each paired with rich functional genomics data. This resource empowers the design of rational combination therapies—pairing EGFR inhibitors with agents targeting parallel pathways such as PI3K, KRAS, or RET—to preempt or overcome resistance. Ultimately, the initiative promises to shorten the drug development cycle, bring more durable treatments to patients, and reinforce the United States’ leadership in precision oncology research.